## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Looking At Thermo Fisher Scientific's Recent Unusual Options Activity**
- Source: Benzinga | 20251211T200858 | Neutral | Relevance: 99%
-  Financial giants have shown unusual bearish options activity for Thermo Fisher Scientific (NYSE: TMO), with significant puts and calls observed. The projected price targets from this activity range from $390.0 to $560.0 over the next three months. Despite this, Thermo Fisher Scientific's stock is currently up by 0.59% at $577.22, and analysts have an average target price of $687.0, with several recent upgrades and positive ratings.

**2. Goldman Sachs initiates Thermo Fisher Scientific stock with Buy rating**
- Source: Investing.com | 20251209T082456 | Bullish | Relevance: 99%
-  Goldman Sachs has initiated coverage on Thermo Fisher Scientific (NYSE:TMO) with a Buy rating and a price target of $685.00, suggesting a 21% upside potential. The investment bank views Thermo Fisher as a "diversified compounder" poised to benefit from increased outsourcing in the life sciences sector, with its proprietary survey indicating higher demand for CDMO services. This positive outlook is supported by robust revenue, recent upgrades from other firms like KeyBanc and Morgan Stanley, and strategic expansions in Asia and successful bond offerings.

**3. Is Thermo Fisher Still Attractively Priced After Recent Share Price Dip In 2025?**
- Source: Yahoo Finance | 20251210T001807 | Somewhat-Bullish | Relevance: 98%
-  Thermo Fisher Scientific's stock has seen a 7.8% year-to-date increase in 2025 but recently dipped, prompting a re-evaluation of its attractiveness. A Discounted Cash Flow analysis suggests the stock is currently trading at a 7.2% discount to its estimated fair value of $606.56 per share, indicating it is "about right" for its future cash generation. The Price-to-Earnings ratio also aligns with its fair value, trading slightly below industry and peer averages, further suggesting the stock is reasonably priced.

**4. 6,343 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by SVB Wealth LLC**
- Source: MarketBeat | 20251209T125005 | Bullish | Relevance: 98%
-  SVB Wealth LLC recently acquired 6,343 shares of Thermo Fisher Scientific (NYSE:TMO) worth approximately $2.57 million in the second quarter. This purchase comes as Thermo Fisher authorized a $5.0 billion share buyback and declared a quarterly dividend of $0.43 per share, while also beating quarterly earnings estimates. Several other institutional investors have also adjusted their holdings in the medical research company amidst analyst upgrades and a "Moderate Buy" average rating.

**5. Axa S.A. Lowers Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T083456 | Somewhat-Bullish | Relevance: 98%
-  Axa S.A. has reduced its stake in Thermo Fisher Scientific Inc. by 15.9% during the second quarter, selling 82,824 shares and now owning 437,727 shares worth $177,481,000. Meanwhile, other institutional investors like Norges Bank and Soundwatch Capital LLC have acquired significant new stakes in the medical research company. Thermo Fisher Scientific recently reported strong earnings, beating analyst estimates, and announced a stock repurchase program of $5.00 billion, along with a quarterly dividend of $0.43 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Heavy insider selling: $42M sold (14 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.5B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.7% to -0.1% (+3.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-2.94), momentum weakening. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.07% (CS: 38) | Neutral |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | -2.94 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.202x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $578.90
- **Stop Loss:** $554.20 (4.3% risk)
- **Target:** $603.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 55
- **Position Value:** $31,839.50
- **Portfolio %:** 31.84%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*